Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1
Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis.
10.3779/j.issn.1009-3419.2020.102.31
- Author:
Jiamin SHENG
1
;
Xiaoqing YU
2
;
Hui LI
2
;
Yun FAN
2
Author Information
1. Wenzhou Medical University, Wenzhou 325035, China.
2. Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou 310022, China.
- Publication Type:Journal Article
- Keywords:
Brain metastasis;
Immunotherapy;
Lung neoplasms;
PD-1/PD-L1
- From:
Chinese Journal of Lung Cancer
2020;23(11):976-982
- CountryChina
- Language:Chinese
-
Abstract:
Brain metastasis (BM) is a common complication in non-small cell lung cancer (NSCLC), which associates with poor prognosis. Recently, immune checkpoint inhibitors (ICIs) has revolutionized the treatment of tumors. Programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors could produce antitumor effect by activating the autoimmune system. The immunotherapy has already show to have a promising outcome for NSCLC patients with BM, while its specific curative effect and the most ideal mode of the treatment remain to be explored. Here we reviewed the tumor microenvironment (TME) in BM lesions and summarized the role of PD-1/PD-L1 inhibitors in cerebral and its current status in clinical studies.
.
